Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single‐arm study
James R. Berenson(American Society of Clinical Oncology), Regina A. Swift(Institute for Myeloma & Bone Cancer Research), David S. Siegel(Hackensack Meridian Health), Syed Jilani(Eye Care Associates), Edward A. Stadtmauer(University of Pennsylvania), Marek J. Bozdech, Joseph Volk(Palo Verde Hospital), Jose Lutzky, Kit Russell(Oncotherapeutics (United States)), Ravi Patel(Comprehensive Blood & Cancer Center), J. Talisman Pomeroy, Robert Louie(NovaBay Pharmaceuticals (United States)), Alberto Bessudo(California Cancer Associates for Research and Excellence), Robert A. Moss(Valley Regional Hospital), Ronald G. Steis, Howard Yeh(Covance (United States)), Ralph V. Boccia, Marshall S. Flam, Delina Ferretti(Oncotherapeutics (United States)), Siu‐Fun Wong(University of California, Irvine Medical Center)
Cited by 83
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k